FDA Fires Warning Letter To Sun Pharma; Says Corrections At Cranbury Site Inadequate
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Sun Pharmaceuticals - India's largest company by market capitalization - has been issued a warning letter by U.S. FDA for significant violations of good manufacturing practices at its Cranbury-based manufacturing site